Investors could become cautious in near-term on Moderna, says BofA

BofA analyst Geoff Meacham says there were "few surprises" in Moderna’s Q4 report following the company’s pre-announcement earlier this year, as COVID-19 vaccine revenue beat at $4.86B and EPS missed due to higher than expected operating expenses. Given the $5B in signed APAs was maintained, investors "could become cautious" in the near-term, especially given the likely impact of Moderna’s vaccine patient assistance program and a lack of any updates on its flu vaccine, mRNA-1010, the firm said in a note on its initial thoughts. BofA has a Neutral rating and $200 price target on Moderna shares, which are down $5.57, or 3.5%, to $152.60 in pre-market trading.